United Therapeutics (NASDAQ:UTHR) Price Target Raised to $687.00

United Therapeutics (NASDAQ:UTHR) had its price objective increased by JPMorgan Chase & Co. from $685.00 to $687.00 in a report released on Thursday morning,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock.

Other research analysts have also recently issued research reports about the stock. TD Cowen restated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a report on Thursday, June 11th. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Royal Bank Of Canada boosted their price target on shares of United Therapeutics from $701.00 to $704.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Finally, Morgan Stanley set a $516.00 price objective on United Therapeutics in a research report on Thursday, May 7th. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $648.33.

United Therapeutics Trading Down 0.2%

UTHR opened at $528.47 on Thursday. The stock’s 50-day moving average price is $547.88 and its 200 day moving average price is $531.39. United Therapeutics has a 12-month low of $272.12 and a 12-month high of $609.35. The firm has a market cap of $22.43 billion, a price-to-earnings ratio of 19.51, a PEG ratio of 1.77 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business’s revenue was down 1.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $6.63 earnings per share. On average, research analysts forecast that United Therapeutics will post 26.65 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Jan Malcolm sold 325 shares of United Therapeutics stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $550.59, for a total value of $178,941.75. Following the completion of the transaction, the director owned 450 shares in the company, valued at $247,765.50. The trade was a 41.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $552.56, for a total transaction of $4,586,248.00. Following the transaction, the executive vice president owned 45,172 shares of the company’s stock, valued at $24,960,240.32. This trade represents a 15.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 513,333 shares of company stock worth $286,933,042. Company insiders own 8.60% of the company’s stock.

Institutional Investors Weigh In On United Therapeutics

Institutional investors have recently modified their holdings of the company. Handelsbanken Fonder AB grew its stake in shares of United Therapeutics by 4.1% during the second quarter. Handelsbanken Fonder AB now owns 13,120 shares of the biotechnology company’s stock worth $7,109,000 after purchasing an additional 520 shares in the last quarter. PensionDanmark Pensionsforsikringsaktieselskab raised its stake in United Therapeutics by 7.4% in the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 11,058 shares of the biotechnology company’s stock valued at $5,992,000 after buying an additional 760 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in United Therapeutics by 79.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 84,538 shares of the biotechnology company’s stock worth $45,805,000 after buying an additional 37,355 shares during the last quarter. GAMMA Investing LLC lifted its holdings in United Therapeutics by 10.3% during the 2nd quarter. GAMMA Investing LLC now owns 1,769 shares of the biotechnology company’s stock worth $958,000 after buying an additional 165 shares during the last quarter. Finally, Versant Capital Management Inc boosted its position in shares of United Therapeutics by 93.6% during the 2nd quarter. Versant Capital Management Inc now owns 182 shares of the biotechnology company’s stock worth $99,000 after acquiring an additional 88 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.